DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced that the centralized European Medicines Agency (“EMEA”) has provided positive formal responses to Neoprobe’s scientific advice submission regarding RIGScan CR and the pathway to receive a marketing authorization for the drug.
